Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Headache

John Mottershead describes the diagnostic headache consultation, before moving on to look at some of the different headache disorders. He provides up-to-date information on the best approaches to management of the most frequently encountered conditions, and includes a summary of non-pharmacological approaches and new treatments for headache
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954–76.
2. Thomson AN, White GE, West R. The prevalence of bad headaches including migraine in a multiethnic community. N Z Med J 1993;106(967):477–80.
3. International Headache Society. International Classification of Headache Disorders, 3rd edition. 2018. https://ichd-3.org
4. Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013;53(2):413–19.
5. Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 2021;397(10283):1496–504.
6. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78(17):1337–45.
7. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921–36.
8. Wakerley BR. Medication-overuse headache. Pract Neurol 2019;19(5):399–403.
9. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opin Biol Ther 2019;19(12):1307–17.